The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process

Circulation

Volumn 111, Issue 13, 2005, Pages 1697-1702

  Roden, Dan M ^a   Temple, Robert ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug approval; Drugs, cardiovascular; Risk factors; Trials; US Food and Drug Administration

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BOSENTAN; CARDIOVASCULAR AGENT; CARVEDILOL; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DOXAZOSIN; ENOXAPARIN; EPTIFIBATIDE; FENOLDOPAM; HIRULOG; HYDRALAZINE; IRBESARTAN; ISOSORBIDE; MIBEFRADIL; MILRINONE; NESIRITIDE; NITRIC OXIDE; PRAVASTATIN; SOTALOL; TASOSARTAN; TIROFIBAN; UNINDEXED DRUG; UNIPROST; VALSARTAN;

ADVISORY COMMITTEE; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL PRACTICE; OUTCOMES RESEARCH; PERIPHERAL VASCULAR DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYNCOPE; TORSADE DES POINTES; UNITED STATES;

CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DRUG APPROVAL; HUMANS; LONG QT SYNDROME; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 17144391455     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000161370.77463.0F     Document Type: Article

References (27)

1. Fleming T, Borer J, Armstrong PW, Pfeffer M; Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. Circulation. 2003;107:e9002-e9003.
2. Fleming T, Borer J, Lipicky R, Armstrong PW. Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. Circulation. 2001;104:e9039.
3. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
4. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
5. US Food and Drug Administration. The Clinical Evaluation of QT/QTc Interval Prolongation and 12 Porarrhythmic. Potential for Non-Antiarrhythmic Drugs. Preliminary Concept Paper. Available at: www.fda.gov/cder/guidance/ 6378dft.pdf. Accessed March 2, 2005.
6. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur Heart J. 2000;21:1216-1231.
7. Anderson ME, Al Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J. 2002;144:769-781.
8. Roden DM. Drug-induced prolongation of the QT Interval. N Engl J Med. 2004;350:1013-1022.
9. Fleming T, Nissen SE, Borer JS, Armstrong PW. Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003; Gaithersburg, Md. Circulation. 2004;109:e9004-e9005.
10. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24:619-625.
11. Moye LA. End-point interpretation in clinical trials: the case for discipline. Control Clin Trials. 1999;20:40-49.
12. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
13. Coats AJ. CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI. Int J Cardiol. 2001;78:109-113.
14. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993;329:149-155.
15. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F III, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
17. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
18. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-1428.
19. Roden DM. Cardiovascular and Renal Advisory Panel of the US Food and Drug Administration considers four drugs. Circulation. 1997;95:2335.
20. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339:436-443.
21. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
22. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414-1421.
23. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med. 2000;133:464-470.
24. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455-463.
25. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
26. Roden DM. Cardiovascular and Renal Advisory Panel of the FDA. Circulation. 1998;97:1107.
27. Pina I. FDA panel votes against approval for bivalirudin. Circulation. 1999;99:1277.